Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 8:8:212305.
doi: 10.7573/dic.212305. eCollection 2019.

Ketamine as treatment for post-traumatic stress disorder: a review

Felix Liriano  1 , Candace Hatten  2 , Thomas L Schwartz  1
Affiliations
Review

Ketamine as treatment for post-traumatic stress disorder: a review

Felix Liriano et al. Drugs Context. .

Abstract

Post-traumatic stress disorder (PTSD) continues to make headlines given multiple military engagements across the world and civilian traumas, and resultant PTSD development continues at an even pace. Currently, antidepressant and cognitive-behavioral therapy have the greatest evidence base but still do not yield a remission of PTSD symptoms in many patients. Off-label and novel treatments continue to be considered for more refractory and disabling cases of PTSD. Ketamine is one such treatment that has been discussed and utilized more often for treatment-resistant major depressive disorder (MDD). Its mechanism is controversial regarding its potential to create anxiety, but the perceived benefit of a rapid reduction of symptoms makes it worthy for study in animal models of, and possibly human studies in, PTSD. The current literature and theoretical mechanism of action is discussed in this manuscript.

Keywords: N-methyl-D-aspartate; acute stress; brain-derived neurotropic factor; ketamine; off-label use; post-traumatic stress disorders; psychological substance-related disorders; receptors; stress disorders; traumatic.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2019/03/dic.212305-COI.pdf

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
    1. Office of Quality and Performance and the Veterans Affairs and Department of Defense Development Work Group. Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 3.0. Washington, DC: Veterans Health Administration and Department of Defense; 2017.
    1. Feder A, Murrough JW. Ketamine for posttraumatic stress disorder. JAMA Psychiatry. 2015;72(1):95. doi: 10.1001/jamapsychiatry.2014.1621. - DOI - PubMed
    1. Krystal JH, Abdallah CG, Averill LA, et al. Synaptic loss and the pathophysiology of PTSD: implications for ketamine as a prototype novel therapeutic. Curr Psychiatry Rep. 2017;19(10):74. doi: 10.1007/s11920-017-0829-z. - DOI - PMC - PubMed
    1. Brachman RA, Mcgowan JC, Perusini JN, et al. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol Psychiatry. 2016;79(9):776–786. doi: 10.1016/j.biopsych.2015.04.022. - DOI - PMC - PubMed